	US 12,257,222 B2
	Nutritional product
Maura O'Donnell, Hightown (GB); Bridget Lambert, Liverpool (GB); Patricia Wallis, Liverpool (GB); Patricia Rutherford, Liverpool (GB); Simon Heales, London (GB); Sean-David Hughes, London (GB); Helen Cross, London (GB); and Simon Eaton, London (GB)
Assigned to VITAFLO (INTERNATIONAL) LTD, Liverpool (GB); and UCL BUSINESS LTD, London (GB)
Filed by VITAFLO (INTERNATIONAL) LTD, Liverpool (GB); and UCL BUSINESS PLC, London (GB)
Filed on May 17, 2022, as Appl. No. 17/746,250.
Application 17/746,250 is a continuation of application No. 14/406,957, granted, now 11,344,522, previously published as PCT/GB2013/051561, filed on Jun. 14, 2013.
Claims priority of provisional application 61/704,277, filed on Sep. 21, 2012.
Claims priority of application No. 1210699 (GB), filed on Jun. 15, 2012.
Prior Publication US 2022/0273602 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/20 (2006.01); A23L 33/12 (2016.01); A61K 31/19 (2006.01); A61K 31/70 (2006.01); A61K 38/02 (2006.01)

CPC A61K 31/20 (2013.01) [A23L 33/12 (2016.08); A61K 31/19 (2013.01); A61K 31/70 (2013.01); A61K 38/02 (2013.01); A23V 2002/00 (2013.01)]

29 Claims

1. A method for treatment of mitochondrial dysfunction associated with muscle and arising through inherited or acquired mutations in nuclear and/or mitochondrial DNA, the method comprising administering a composition to an individual having the mitochondrial dysfunction, the composition comprising an effective amount of a combination of decanoic acid and octanoic acid in the form of triglycerides having a weight ratio of the decanoic acid to the octanoic acid of at least 2:1.